VBI Vaccines Inc. has announced that it has entered into a debt financing facility for up to $50 million with K2 HealthVentures. As VBI advances its pipeline candidates through the next clinical and regulatory milestones, the partnership will strengthen the company’s financial position and flexibility.
VBI Vaccines is a commercial-stage biopharmaceutical company developing next-generation infection disease and immuno-oncology vaccines.